Next Article in Journal
Fabrication and Optimization of Stable, Optically Transparent, and Reusable pH-Responsive Silk Membranes
Next Article in Special Issue
Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer
Previous Article in Journal
Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
Previous Article in Special Issue
Towards Stratified Medicine in Plasma Cell Myeloma
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(11), 1890;

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung 204, Taiwan
Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Linkou and Keelung 105, Taiwan
Institute of Pharmacology, School of Medicine, Infection and Immunity Research Center, National Yang-Ming University, Taipei 112, Taiwan
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 28 September 2016 / Revised: 7 November 2016 / Accepted: 7 November 2016 / Published: 15 November 2016
(This article belongs to the Special Issue Precision Medicine—From Bench to Bedside)
Full-Text   |   PDF [522 KB, uploaded 15 November 2016]   |  


Severe cutaneous adverse reactions (SCARs), previously thought to be idiosyncratic or unpredictable, are a deadly form of adverse drug reactions with skin manifestations. Current pharmacogenomic studies of SCARs have made important strides, as the prevention of SCARs, to some extent, appears attainable with the identification of genetic variants for genes encoding drug-metabolizing enzymes and human leukocyte antigens (HLAs). Despite the improvement of incidence, a treatment guideline for this devastating condition is still unavailable, highlighting the inadequacy of contemporary accepted therapeutic interventions. As such, prompt withdrawal of causative drugs is believed to be a priority of patient management. In this review, we discuss recent cutting-edge findings concerning the discovery of biomarkers for SCARs and their clinical utilities in the better prediction and early diagnosis of this disease. The knowledge compiled herein provides clues for future investigations on deciphering additional genetic markers for SCARs and the design of clinical trials for the prospective identification of subjects at genetic risk for this condition, ultimately personalizing the medicine. View Full-Text
Keywords: severe cutaneous adverse reactions; pharmacogenomics; clinical implementation severe cutaneous adverse reactions; pharmacogenomics; clinical implementation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Su, S.-C.; Hung, S.-I.; Fan, W.-L.; Dao, R.-L.; Chung, W.-H. Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation. Int. J. Mol. Sci. 2016, 17, 1890.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top